| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 30/gram
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Veliparib, also known as ABT-888, is a potent and selective Poly (ADP-Ribose) Polymerase (PARP) Inhibitor. Veliparib enhances apoptosis and autophagy in response to treatments that cause DNA breaks, including radiation and DNA alkylation. ABT-888 is an orally bioavailable inhibitor of PARP1 and PARP2.
ABT-888 effectively inhibits PARP, with Ki values of 5.2 and 2.9 nM when acting on PARP-1 and PARP-2, respectively. ABT-888 reduces the survival rate of cloned genes in lung cancer H460 cells and inhibits DNA repair. The combination of ABT-888 and radiation reduces the formation of tumor blood vessels. ABT-888 delays the growth of tumor Chemicalbook of NCI-H460 xenograft model. ABT-888 inhibits PARP in B16F10 and 9L xenograft tumor models, thereby enhancing the anticancer activity of temozolomide.
| Ketoconazole | Dyclonine hydrochloride | Fluconazole | Loteprednol Etabonate |
| Sevelamer HCl | Sevelamer Carbonate | Cyproheptadine hydrochloride | Sodium picosulfate |
| Mexidol succinate | Lansoprazole | Bisacodyl | Mexidol hydrochloride |
){kind=link}